Dudediligence.

Mirum Pharmaceuticals, Inc

MIRMNASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

64.8M

on 2026-06-30, from 47.1M on 2024-03-31 10-Q ↗

20M40M60MMar2024JunSepDecMar2025JunSepDecMar2026Jun

Newest

No limit

S-3ASR of 2025-08-12. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗

$200.0M

Leerink Partners, agreement of 2025-08-12. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗

Warrants

The 10-Q filed 2026-08-05 is not read yet.

Cash

7.7 quarters

$438.3M on 2026-06-30 ÷ $56.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 1 of its filings are not read yet.

Also on file: $90.0M convertible notes, 2026-05-15 8-K ↗